Your browser doesn't support javascript.
loading
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka, T; Komatsu, Y; Mizuno, N; Tsuji, A; Ohkawa, S; Tanaka, M; Iguchi, H; Ishiguro, A; Kitano, M; Satoh, T; Yamaguchi, T; Takeda, K; Kida, M; Eguchi, K; Ito, T; Munakata, M; Itoi, T; Furuse, J; Hamada, C; Sakata, Y.
Afiliação
  • Ioka T; Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan.
  • Komatsu Y; Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, 5-chome, Kita 14 Jou Nishi, Kita-ku, Sapporo 060-8648, Japan.
  • Mizuno N; Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
  • Tsuji A; Department of Medical Oncology, Kochi Health Sciences Center, 2125-1 Ike, Kochi 781-0111, Japan.
  • Ohkawa S; Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center Hospital, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan.
  • Tanaka M; Department of Surgery and Oncology, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
  • Iguchi H; Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-chou, Matsuyama 791-0280, Japan.
  • Ishiguro A; Department of Medical Oncology, Hirosaki University, 53 Hon-cho, Hirosaki 036-8562, Japan.
  • Kitano M; Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2 Onohigashi, Osakasayama 589-8511, Japan.
  • Satoh T; Faculty of Medicine, Department of Medical Oncology, Kinki University, 377-2 Onohigashi, Osakasayama 589-8511, Japan.
  • Yamaguchi T; Division of Gastroenterology, Chiba Cancer Center Hospital, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan.
  • Takeda K; Department of Clinical Oncology, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojia-ku, Osaka 534-0021, Japan.
  • Kida M; Department of Medicine, Kitasato University School of Medicine, 2-1-1 Asamizodai, Minami-ku, Sagamihara 252-0374, Japan.
  • Eguchi K; Department of Internal Medicine, Medical Oncology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8605, Japan.
  • Ito T; Department of Medicine and Bioregulatory Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
  • Munakata M; Department of Medical Oncology, Misawa City Hospital, 164-65 Oazamisawaazahoriuchi, Misawa 033-0022, Japan.
  • Itoi T; Department of Gastroenterological Medicine, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 166-0023, Japan.
  • Furuse J; Department of Medical Oncology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, 181-8611, Japan.
  • Hamada C; Faculty of Engineering, Tokyo University of Science, 6-3-1 Niijuku, Katsushika-ku, Tokyo 125-8585, Japan.
  • Sakata Y; Department of Medical Oncology, Misawa City Hospital, 164-65 Oazamisawaazahoriuchi, Misawa 033-0022, Japan.
Br J Cancer ; 116(4): 464-471, 2017 Feb 14.
Article em En | MEDLINE | ID: mdl-28081543

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Oxônico / Neoplasias Pancreáticas / Camptotecina / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Tegafur / Resistencia a Medicamentos Antineoplásicos / Desoxicitidina Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Oxônico / Neoplasias Pancreáticas / Camptotecina / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Tegafur / Resistencia a Medicamentos Antineoplásicos / Desoxicitidina Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article